The French LIBER Trial is studying the effect of letrozole, given at a dose of 2.5 mg daily for 5 years, in the primary prevention of breast cancer among 171 unaffected postmenopausal women aged 40 - 70 years with BRCA1 or BRCA2 mutation [72, 73]. Here, BRCA2 is linked to breast cancer.